Mineralys Therapeutics (MLYS) News Today $13.73 -0.05 (-0.36%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$13.00 -0.73 (-5.32%) As of 06/18/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Research Analysts Issue Forecasts for MLYS Q2 EarningsMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Equities researchers at Lifesci Capital issued their Q2 2025 earnings estimates for Mineralys Therapeutics in a report released on Tuesday, June 17th. Lifesci Capital analyst R. Katkhuda expects that the company will earn ($0.81) per sharJune 19 at 7:06 AM | marketbeat.comPromising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment AppealJune 18 at 5:07 AM | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Given Buy Rating at HC WainwrightJune 18 at 2:35 AM | americanbankingnews.comMineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock JumpsJune 17 at 3:31 PM | benzinga.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.6% - Should You Buy?Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.6% - Time to Buy?June 17 at 2:59 PM | marketbeat.comMineralys Therapeutics' (MLYS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $42.00 price objective on shares of Mineralys Therapeutics in a research report on Tuesday.June 17 at 12:51 PM | marketbeat.comPositive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy RatingJune 17 at 12:18 PM | tipranks.comMineralys Therapeutics stock jumps after positive kidney disease trial dataJune 17 at 10:30 AM | investing.comMineralys Therapeutics Shares Climb on Strong Results from Kidney Disease TrialJune 17 at 10:30 AM | msn.comMineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and AlbuminuriaJune 17 at 7:00 AM | globenewswire.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.5% - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.5% - Should You Sell?June 16 at 4:45 PM | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street ZenWall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday.June 14, 2025 | marketbeat.comJefferies initiates Mineralys Therapeutics stock with hold ratingJune 12, 2025 | uk.investing.comJefferies Initiates Coverage of Mineralys Therapeutics (MLYS) with Hold RecommendationJune 12, 2025 | msn.comWellington Management Group LLP Has $1.13 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Wellington Management Group LLP increased its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 43.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,529 shares of the company's stock afJune 7, 2025 | marketbeat.comMineralys Therapeutics: Merits A Small 'Speculative' HoldingJune 3, 2025 | seekingalpha.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.9% - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 4.9% - Here's What HappenedMay 31, 2025 | marketbeat.comPolar Asset Management Partners Inc. Raises Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Polar Asset Management Partners Inc. lifted its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 144.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 99,100 shares of the company's stock after buying an additional 58,60May 28, 2025 | marketbeat.comMineralys announces late-breaking presentation of data from Launch-HTN trialMay 27, 2025 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Position Lifted by Millennium Management LLCMillennium Management LLC raised its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 1,015.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,101,674 shares of the company's stock afterMay 26, 2025 | marketbeat.comMineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)May 24, 2025 | globenewswire.comBalyasny Asset Management L.P. Takes $219,000 Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Balyasny Asset Management L.P. acquired a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 17,786 shares of the company's sMay 21, 2025 | marketbeat.comMineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular ProtectionMay 20, 2025 | globenewswire.comTema Etfs LLC Buys New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Tema Etfs LLC bought a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 89,529 shares of the company's stock, valued at approximately $1,102,000.May 20, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires Shares of 16,412 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Dimensional Fund Advisors LP acquired a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 16,412 shares of the company's stock, valued at approximately $202,000.May 20, 2025 | marketbeat.comPolar Asset Management Partners Inc. Has $1.22 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Polar Asset Management Partners Inc. lifted its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 144.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 99,100 shares of the cMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Has $2.35 Million Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Sphera Funds Management LTD. lessened its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 30.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 190,672 shares of the company's stock after selling 81,800 shares during the periMay 18, 2025 | marketbeat.comMineralys at BofA Securities 2025: Lorundrostat’s Hypertension PromiseMay 16, 2025 | investing.comDavid Malcom Rodman Sells 11,366 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMay 16, 2025 | insidertrades.comHC Wainwright Reaffirms "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)HC Wainwright reissued a "buy" rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday.May 15, 2025 | marketbeat.comOrbimed Advisors LLC Sells 391,302 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Orbimed Advisors LLC reduced its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 19.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,611,637 shares of the company's stock after selling 391,302 shares durMay 15, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.23 EPSMineralys Therapeutics (NASDAQ:MLYS - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.23.May 14, 2025 | marketbeat.comEarnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock risesMay 14, 2025 | uk.investing.comIntegral Health Asset Management LLC Buys 519,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Integral Health Asset Management LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 145.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 875,000 shares of the company's stock after purchasing an addMay 14, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comPositive Buy Rating for Lorundrostat Driven by Successful Trials and Future PotentialMay 13, 2025 | tipranks.comOptimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data ReleasesMay 13, 2025 | tipranks.comMineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 13, 2025 | finance.yahoo.comMineralys Therapeutics stock rises on better-than-expected Q1 resultsMay 13, 2025 | investing.comMineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call TranscriptMay 12, 2025 | seekingalpha.comMineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 12, 2025 | globenewswire.comMineralys Therapeutics to Present at Bank of America Health Care ConferenceMay 11, 2025 | msn.comUncovering Potential: Mineralys Therapeutics's Earnings PreviewMay 9, 2025 | benzinga.comMineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12May 7, 2025 | nasdaq.comMineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceMay 7, 2025 | globenewswire.comMineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025May 5, 2025 | globenewswire.comAdams Street Partners LLC Sells 402,847 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Adams Street Partners LLC lowered its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 26.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,129,807 shares of the company's stock after selling 402,84May 4, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Caligan Partners LPCaligan Partners LP increased its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,011,155 shares of the company's stock after acquiring an additional 30,May 3, 2025 | marketbeat.comMineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on ThursdayMineralys Therapeutics (NASDAQ:MLYS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-mineralys-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Hits New 52-Week High - Should You Buy?Mineralys Therapeutics (NASDAQ:MLYS) Hits New 52-Week High - Here's What HappenedMay 3, 2025 | marketbeat.com Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.460.69▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼145▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTGX News Today SRRK News Today KYMR News Today VKTX News Today HCM News Today CRNX News Today CPRX News Today MOR News Today MTSR News Today ALVO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.